Ezio Bonvini

8.3k total citations
145 papers, 5.0k citations indexed

About

Ezio Bonvini is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Ezio Bonvini has authored 145 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Immunology, 54 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in Ezio Bonvini's work include Monoclonal and Polyclonal Antibodies Research (45 papers), CAR-T cell therapy research (30 papers) and Immune Cell Function and Interaction (23 papers). Ezio Bonvini is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (45 papers), CAR-T cell therapy research (30 papers) and Immune Cell Function and Interaction (23 papers). Ezio Bonvini collaborates with scholars based in United States, Italy and Sweden. Ezio Bonvini's co-authors include Scott Koenig, Syd Johnson, Sergey Gorlatov, Jorge Laborda, Paul A. Moore, Ling Huang, Hua Li, María José Ruiz‐Hidalgo, Karen E. DeBell and Thomas Hoffman and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ezio Bonvini

140 papers receiving 4.8k citations

Peers

Countries citing papers authored by Ezio Bonvini

Since Specialization

Citations

This map shows the geographic impact of Ezio Bonvini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ezio Bonvini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ezio Bonvini more than expected).

Fields of papers citing papers by Ezio Bonvini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ezio Bonvini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ezio Bonvini. The network helps show where Ezio Bonvini may publish in the future.

Co-authorship network of co-authors of Ezio Bonvini

This figure shows the co-authorship network connecting the top 25 collaborators of Ezio Bonvini. A scholar is included among the top collaborators of Ezio Bonvini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ezio Bonvini. Ezio Bonvini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Patrizia Perri, (unknown), Maria Valeria Corrias, Simonetta Astigiano, Michele Cilli, (unknown), Ezio Bonvini, Fabio Pastorino, Mirco Ponzoni	16
2	Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia 2022 ·Journal of Clinical Medicine ·Sonali P. Barwe, Anne Kisielewski, Ezio Bonvini, John Muth, Jan Davidson‐Moncada, E. Anders Kolb, Anilkumar Gopalakrishnapillai	4
3	1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours 2020 ·Annals of Oncology ·Monica Sharma, (unknown), (unknown), J. C. Bendell, Sanjeev Kaul, (unknown), (unknown), Paul A. Moore, Ezio Bonvini, (unknown), (unknown)	7
4	Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies 2017 ·Blood ·Michael P. Rettig, John E. Godwin, Norbert Vey, Bernard A. Fox, Carmen Ballesteros‐Merino, Carlo Bifulco, Daner Li, (unknown), (unknown), Jichao Sun, Hélène Lelièvre, Jan Baughman, (unknown), John Muth, Paul A. Moore, Ezio Bonvini, Jon M. Wigginton, John F. DiPersio, Jan Davidson‐Moncada	10
5	MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies 2016 ·Clinical Cancer Research ·Liqin Liu, Chia‐Ying K. Lam, (unknown), (unknown), Yinhua Yang, Hua Li, Linda X. Jin, Steve Burke, Sergey Gorlatov, Jennifer G. Brown, Ralph Alderson, (unknown), Jeffrey L. Nordstrom, Scott Koenig, Paul A. Moore, Syd Johnson, Ezio Bonvini	59
6	Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties 2011 ·Breast Cancer Research ·Jeffrey L. Nordstrom, Sergey Gorlatov, Wenjun Zhang, Yinhua Yang, Ling Huang, Steve Burke, Hua Li, Valentina Ciccarone, Téngfēi Zhāng, Jeffrey B. Stavenhagen, Scott Koenig, Stanford J. Stewart, Paul A. Moore, Syd Johnson, Ezio Bonvini	183
7	Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold 2010 ·Arthritis & Rheumatism ·Maria-Concetta Verı́, Stephen Burke, Ling Huang, Hua Li, Sergey Gorlatov, Nadine Tuaillon, G. Jonah Rainey, Valentina Ciccarone, Téngfēi Zhāng, (unknown), Linda X. Jin, (unknown), (unknown), Paul A. Moore, Scott Koenig, Syd Johnson, Ezio Bonvini	59
8	Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors 2007 ·Cancer Research ·Jeffrey B. Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, Christopher T. Rankin, Hua Li, Stephen Burke, Ling Huang, Syd Johnson, Ezio Bonvini, Scott Koenig	211
9	Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells 2005 ·Proceedings of the National Academy of Sciences ·Kavita M. Dhodapkar, (unknown), Marc Ehlers, Devi Banerjee, Ezio Bonvini, Scott Koenig, Ralph M. Steinman, Jeffrey V. Ravetch, Madhav V. Dhodapkar	195
10	A New Tyrosine Phosphorylation Site in PLCγ1: The Role of Tyrosine 775 in Immune Receptor Signaling 2005 ·The Journal of Immunology ·Carmen J. Serrano, Laurie Graham, Karen E. DeBell, Rashmi Rawat, Maria Veri, Ezio Bonvini, Barbara L. Rellahan, Ilona Reischl	40
11	70Z/3 Cbl induces PLCγ1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism 2003 ·Oncogene ·Laurie Graham, Maria-Concetta Verı́, Karen E. DeBell, (unknown), Rashmi Rawat, (unknown), Ezio Bonvini, Barbara L. Rellahan	6
12	Differential effects of Cbl and 70Z/3 Cbl on T cell receptor‐induced phospholipase Cγ‐1 activity 2000 ·FEBS Letters ·Laurie Graham, Karen E. DeBell, Maria-Concetta Verı́, Bogdan A. Stoica, Howard Mostowski, Ezio Bonvini, Barbara L. Rellahan	13
13	Functional Independence and Interdependence of the Src Homology Domains of Phospholipase C-γ1 in B-Cell Receptor Signal Transduction 1999 ·Molecular and Cellular Biology ·Karen E. DeBell, Bogdan A. Stoica, Maria-Concetta Verı́, Angela Di Baldassarre, Sebastianó Miscia, Laurie Graham, Barbara L. Rellahan, Masamichi Ishiai, Tomohiro Kurosaki, Ezio Bonvini	33
14	Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk 1999 ·Differentiation ·Cármen Garcés, María José Ruiz‐Hidalgo, Ezio Bonvini, Julia Goldstein, Jorge Laborda	106
15	Sequences Surrounding the Src-Homology 3 Domain of Phospholipase Cγ-1 Increase the Domain's Association with Cbl 1998 ·Biochemical and Biophysical Research Communications ·Laurie Graham, Bogdan A. Stoica, Marjorie A. Shapiro, Karen E. DeBell, Barbara L. Rellahan, Jorge Laborda, Ezio Bonvini	19
16	Notch-1 Controls the Expression of Fatty Acid-activated Transcription Factors and Is Required for Adipogenesis 1997 ·Journal of Biological Chemistry ·Cármen Garcés, María José Ruiz‐Hidalgo, Jaime Font de Mora, Crystal L. Park, Lucio Miele, Julia Goldstein, Ezio Bonvini, Almudena Porrás, Jorge Laborda	136
17	Inhibition of release of arachidonic acid, superoxide, and IL-1 from human monocytes by monoclonal anti-HLA class II antibodies: Effects at proximal and distal points of inositol phospholipid hydrolysis pathway 1992 ·Inflammation ·Joseph Puri, (unknown), María A. Álava, Ezio Bonvini, Thomas Hoffman	5
18	Differential turnover of enzymes involved in human monocyte eicosanoid metabolism 1992 ·Biochemical Pharmacology ·Thomas Hoffman, Young Lim Lee, Elaine F. Lizzio, Anil Kumar Tripathi, Ezio Bonvini, Joseph Puri	5
19	T lymphocyte aggregation with immobilized anti-TCR-antibodies is dependent upon energy and microfilament assembly 1990 ·Cellular Immunology ·Karen E. DeBell, (unknown), Thomas Hoffman, Ezio Bonvini	2
20	Dual stimulation of phospholipase activity in human monocytes. Role of calcium-dependent and calcium-independent pathways in arachidonic acid release and eicosanoid formation. 1988 ·The Journal of Immunology ·Thomas Hoffman, Elaine F. Lizzio, (unknown), Daniel Rotrosen, J A Sullivan, G. L. Mandell, Ezio Bonvini	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact